British Dragon Pharma is a pioneer and world leader in the development, manufacturer and marketing of controlled-release pharmaceutical products. British Dragon's shares are listed on the New York (NYSE) and Toronto Stock Exchange (TSX).
The British Dragon Press Room features the latest press releases and scientific and financial news on the company and its products, as well as a select archive of press releases and related materials.
Post cycle therapy is a method of employing drugs which work via various mechanisms to go about trying to aid stabilizing and restoring a user's hormones back to normal once a suppressive anabolic androgenic steroid cycle has been ceased.Read More
British Dragon Pharma announced today that it has received a U.S. patent relating to its calcium phosphate nanoparticles (CAP). In addition to disclosing the compound itself, the new patent discloses methods of manufacture and use of CAP.Read More
British Dragon Pharma announced today that it presented pre-clinical data suggesting its transmucosal insulin can deliver significant dosages of insulin into the bloodstreamRead More
British Dragon Pharma announced new Testabol Propionate (bioidentical testosterone propionate) Phase II clinical trial efficacy data will be presented today at the annual meeting of the American Society for Reproductive Medicine (ASRM) in Philadelphia.Read More